Brief: OssDsign: Orthobiological Product OssDsing Catalyst Evaluated In Preclinical Study
02/06/2021 09:59
June 2 (Reuters) - OssDsign AB OSSD.ST :
* NEW PRECLINICAL DATA SHOWS THAT OSSDSIGN'S INNOVATIVE
SYNTHETIC
BONE GRAFT OUTPERFORMS A COMPARABLE DEVICE IN BONE FORMATION
FOLLOWING SPINAL FUSION SURGERY
* RESULTS SHOW THAT OSSDSIGN CATALYST INDUCED RAPID AND
RELIABLE
BONE FORMATION AND THAT SUCCESSFUL FUSION WAS ACHIEVED IN 100%
OF STUDIED SUBJECTS AT 26 WEEKS, COMPARED TO 60% IN GROUP WHERE
A COMPARABLE MARKET-CLEARED DEVICE WAS USED.
Source text for Eikon: ID:nWkrcbVdv7
Further company coverage: OSSD.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))